Prothrombin Fragment F 1+2 Levels are High in NIDDM Patients Independently of the Hb A1 c

• References

• 1 Knöbl P, Schemthaner G, Schnack C, Pietschmann P, Proidl S, Prager R, Vukovich T. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost 1994; 71: 692-697
• 2 Pelzer H, Schwarz A, Stäber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159
• 3 Marongiu F, Conti M, Mameli G, Sorano GG, Cossu E, Cirillo R, Balestrieri A. Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity. Thromb Res 1990; 58: 91-99
• 4 Bruhn HD, Conard J, Mannucci PM, Montegaudo J, Pelzer H, Reverter JC, Samama M, Tripodi A, Wagner C. Multicentric evaluation of a new assay for prothrombin fragment F 1+2 determination. Thromb Haemost 1992; 68: 413-417
• 5 Kirstein M, Brett J, Radoff S, Ogawa S, Stem D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990; 87: 9010-9014